Juniper Pharmaceuticals Fund Company Profile

Description

Juniper Pharmaceuticals, Inc. focuses on developing therapeutics that address unmet medical needs in women's health. The company develops its products using its drug delivery technologies, including bioadhesive delivery system, a polymer designed to adhere to epithelial surfaces or mucosa for sustained and controlled delivery of active drug product; and a novel intra-vaginal ring (IVR) technology. It offers CRINONE, a progesterone gel used for progesterone supplementation or replacement in infertile women with progesterone deficiency. The company is also developing COL-1077, a 10% lidocaine bioadhesive gel, which is in Phase 2b clinical trial for use as an acute use anesthetic for pain from minimally invasive gynecological procedures. Its products in preclinical development include JNP-0101, an oxybutynin IVR to treat overactive bladder; JNP-0201, a product candidate with natural progesterone and natural estradiol for used in hormone replacement therapy in menopausal women; and JNP-0301, a progesterone IVR used for the prevention of preterm birth. In addition, Juniper Pharmaceuticals, Inc. provides pharmaceutical development, clinical trial manufacturing, analytical, and consulting services. The company was formerly known as Columbia Laboratories, Inc. and changed its name to Juniper Pharmaceuticals, Inc. in April 2015. Juniper Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Boston, Massachusetts.